Literature DB >> 33673595

Enterovirus A71 Vaccines.

Mei-Ling Li1, Shin-Ru Shih2,3,4,5, Blanton S Tolbert6, Gary Brewer1.   

Abstract

Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina. Moreover, EV-A71 infection can lead to neurological complications and death. Vaccination is the most efficient way to control virus infection. There are currently three inactivated, whole EV-A71 vaccines licensed by the China NMPA (National Medical Products Administration). Several other types of vaccines, such as virus-like particles and recombinant VP1 (capsid protein), are also under development. In this review, we discuss recent advances in the development of EV-A71 vaccines.

Entities:  

Keywords:  Enterovirus A71; Sinovac; foot and mouth disease (HFMD); hand; vaccine

Year:  2021        PMID： 33673595      PMCID： PMC7997495          DOI： 10.3390/vaccines9030199

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN： 2076-393X


  75 in total

1.  Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides.

Authors:  Damian Guang Wei Foo; Sylvie Alonso; Meng Chee Phoon; N P Ramachandran; Vincent Tak Kwong Chow; Chit Laa Poh
Journal:  Virus Res       Date:  2007-01-12       Impact factor: 3.303

2.  Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys.

Authors:  Chenghong Dong; Longding Liu; Hongling Zhao; Jingjing Wang; Yun Liao; Xuemei Zhang; Ruixiong Na; Yan Liang; Lichun Wang; Qihan Li
Journal:  Vaccine       Date:  2011-06-29       Impact factor: 3.641

3.  VP1 Amino Acid Residue 145 of Enterovirus 71 Is a Key Residue for Its Receptor Attachment and Resistance to Neutralizing Antibody during Cynomolgus Monkey Infection.

Authors:  Ken Fujii; Yui Sudaka; Ayako Takashino; Kyousuke Kobayashi; Chikako Kataoka; Tadaki Suzuki; Naoko Iwata-Yoshikawa; Osamu Kotani; Yasushi Ami; Hiroyuki Shimizu; Noriyo Nagata; Katsumi Mizuta; Yoko Matsuzaki; Satoshi Koike
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

4.  A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine.

Authors:  Aristine Cheng; Chang-Phone Fung; Chia-Chyi Liu; Yi-Tsung Lin; Hsih-Yeh Tsai; Shan-Chwen Chang; Ai-Hsiang Chou; Jui-Yuan Chang; Ren-Huei Jiang; Yi-Chin Hsieh; Ih-Jen Su; Pele Choi-Sing Chong; Szu-Min Hsieh
Journal:  Vaccine       Date:  2013-03-27       Impact factor: 3.641

Review 5.  Host factors in enterovirus 71 replication.

Authors:  Shin-Ru Shih; Victor Stollar; Mei-Ling Li
Journal:  J Virol       Date:  2011-06-29       Impact factor: 5.103

Review 6.  Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine.

Authors:  Yang Zhou; Jing-Xin Li; Peng-Fei Jin; Yu-Xiao Wang; Feng-Cai Zhu
Journal:  Expert Rev Vaccines       Date:  2016-06-06       Impact factor: 5.217

7.  Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice.

Authors:  Tao Meng; Annasaheb B Kolpe; Tanja K Kiener; Vincent T K Chow; Jimmy Kwang
Journal:  PLoS One       Date:  2011-07-01       Impact factor: 3.240

8.  Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates.

Authors:  Ai-Hsiang Chou; Chia-Chyi Liu; Cheng-Peng Chang; Meng-Shin Guo; Shih-Yang Hsieh; Wen-Hsueh Yang; Hsin-Ju Chao; Chien-Long Wu; Ju-Lan Huang; Min-Shi Lee; Alan Yung-Chi Hu; Sue-Chen Lin; Yu-Yun Huang; Mei-Hua Hu; Yen-Hung Chow; Jen-Ron Chiang; Jui-Yuan Chang; Pele Chong
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

Review 9.  Enterovirus A71 neurologic complications and long-term sequelae.

Authors:  Luan-Yin Chang; Hsiang-Yuan Lin; Susan Shur-Fen Gau; Chin-Yu Lu; Shao-Hsuan Hsia; Yhu-Chering Huang; Li-Min Huang; Tzou-Yien Lin
Journal:  J Biomed Sci       Date:  2019-08-08       Impact factor: 8.410

10.  Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71.

Authors:  Xi Wang; Ke Dong; Min Long; Fang Lin; Zhaowei Gao; Lin Wang; Zhe Zhang; Xi Chen; Ying Dai; Huiping Wang; Huizhong Zhang
Journal:  Arch Virol       Date:  2018-03-27       Impact factor: 2.574
View more
  2 in total

1.  Molecular Epidemiology of Enterovirus A71 in Surveillance of Acute Flaccid Paralysis Cases in Senegal, 2013-2020.

Authors:  Ndack Ndiaye; Fatou Diène Thiaw; Amary Fall; Ousmane Kébé; Khadija Leila Diatta; Ndongo Dia; Malick Fall; Amadou Alpha Sall; Martin Faye; Ousmane Faye
Journal:  Vaccines (Basel)       Date:  2022-05-25

2.  First evidence of enterovirus A71 and echovirus 30 in Uruguay and genetic relationship with strains circulating in the South American region.

Authors:  Andrés Lizasoain; Daiana Mir; Matías Salvo; Viviana Bortagaray; Gisela Masachessi; Adrián Farías; Nélida Rodríguez-Osorio; Silvia Nates; Matías Victoria; Rodney Colina
Journal:  PLoS One       Date:  2021-08-12       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.